Actuate Therapeutics (NASDAQ:ACTU) Upgraded at Wall Street Zen

Actuate Therapeutics (NASDAQ:ACTU) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other equities analysts have also recently issued reports on ACTU. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Actuate Therapeutics in a report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Actuate Therapeutics has an average rating of “Moderate Buy” and an average target price of $20.33.

Actuate Therapeutics Price Performance

Shares of Actuate Therapeutics stock opened at $4.33 on Friday. The stock has a market cap of $100.63 million, a PE ratio of -4.98 and a beta of -0.16. The firm has a fifty day moving average price of $5.85 and a 200 day moving average price of $6.76. Actuate Therapeutics has a 1 year low of $4.04 and a 1 year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02.

Insider Activity at Actuate Therapeutics

In related news, Director Todd S. Thomson sold 280,000 shares of Actuate Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $5.80, for a total value of $1,624,000.00. Following the completion of the transaction, the director owned 904,795 shares in the company, valued at $5,247,811. The trade was a 23.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 69.34% of the stock is owned by company insiders.

Institutional Trading of Actuate Therapeutics

Several institutional investors have recently bought and sold shares of the business. BIOS Capital Management LP increased its position in shares of Actuate Therapeutics by 0.9% in the third quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock valued at $67,234,000 after buying an additional 84,917 shares in the last quarter. Voss Capital LP increased its holdings in Actuate Therapeutics by 45.0% in the 4th quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock worth $7,956,000 after acquiring an additional 403,722 shares in the last quarter. Vanguard Group Inc. raised its position in Actuate Therapeutics by 19.5% during the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock worth $2,114,000 after acquiring an additional 51,546 shares during the period. Geode Capital Management LLC lifted its holdings in Actuate Therapeutics by 42.9% during the fourth quarter. Geode Capital Management LLC now owns 207,744 shares of the company’s stock valued at $1,271,000 after purchasing an additional 62,332 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in Actuate Therapeutics during the fourth quarter valued at $579,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.